NCT07448376Not yet recruiting
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
Exploratory Study on EUS-guided Portal Vein CTCs and Their Subtypes Combined With Multi-omics Detection for Early Warning of Pancreatic Cancer Recurrence and Metastasis
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 25 Feb 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- Huazhong University of Science and Technology
- Diseases
- Pancreatic cancer
- NCT number
- NCT07448376
What you commit to
- Study type: Observational
- Planned participants: 20
- From 1 Mar 2026 to the primary completion date, 30 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received radiotherapy or chemotherapy
Other illness
- Patients with other active malignant tumors
- Patients with hemorrhagic diseases
- Patients with a history of taking anticoagulant drugs such as aspirin and warfarin in the past week
- Patients with absolute contraindications to EUS examination, a history of acute pancreatitis within the past 2 weeks, a history of gastric surgery, pregnancy, severe diseases, or a history of allergy to anesthetics
- Patients whose EUS examination was terminated early due to esophageal stenosis, obstruction, large space-occupying lesions, rapid changes in the patient's heart rate or respiratory rate, patient intolerance, or a large amount of food residue, etc.
- Patients with known hepatitis C virus infection
- Patients with known human immunodeficiency virus (HIV) infection
Lab values
- Patients with coagulation dysfunction (PLT 50,000/mm3, INR \> 1.5; roughly estimated, INR \> 1.5 is approximately equivalent to PT \> 18 seconds)
Other
- Pregnant women
- Patients with imaging examinations, EUS results, etc., suggesting pancreatic cystic space-occupying lesions
- Patients with incomplete pathological information, unable to make a clear diagnosis, or unable to sign the informed consent form
Who the study is looking for
- Patients with solid masses (diameter \> 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion.
- Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT/MRI).
- Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy.
- Signed informed consent form.
- Patients must be able to comply with the trial requirements.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, HUST Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.